FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Korenberg Matthew E		 2. Date of Event Requiring Statement (MM/DD/YYYY)
5/22/2020 

 3. Issuer Name and Ticker or Trading Symbol

Qualigen Therapeutics, Inc. [QLGN]
(Last)        (First)        (Middle)

C/O QUALIGEN THERAPEUTICS, INC.,, 2042 CORTE DEL NOGAL		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

CARLSBAD, CA 92011      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:

Remarks:
On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger, the Reporting Person became a director of the Issuer. Exhibit List - Exhibit 24 - Power of Attorney
No securities are beneficially owned.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Korenberg Matthew E
C/O QUALIGEN THERAPEUTICS, INC.,
2042 CORTE DEL NOGAL
CARLSBAD, CA 92011		X
Signatures
/s/ Hayden Trubitt, Attorney-in-Fact for Matthew E. Korenberg5/27/2020
**Signature of Reporting PersonDate
Ritter Pharmaceuticals (NASDAQ:RTTR)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Ritter Pharmaceuticals.
Ritter Pharmaceuticals (NASDAQ:RTTR)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Ritter Pharmaceuticals.